Pathline customer support now available on our website Learn more

Now available! PanTracer Tissue + HRD Learn more

New PanTracer product now available for Pharma Partners Learn More 

FOLR1 FDA (ELAHERE) for Ovarian Carcinoma

  • Immunohistochemistry (IHC)

The VENTANA FOLR1 (FOLR1-2.1) RxDx Assay is an FDA-approved qualitative immunohistochemical assay using a mouse monoclonal anti-FOLR1 antibody intended for use in the assessment of Folate Receptor alpha (FRα) protein in formalin-fixed, paraffin-embedded (FFPE) ovarian cancer tissue on a VENTANA BenchMark ULTRA instrument. FOLR1 is indicated as an aid in identifying patients with ovarian cancer (including epithelial ovarian cancer, primary peritoneal cancer or primary fallopian tube cancer), whose tumors have FRα expression in ≥75% tumor cells staining at 2+/3+ intensity, who are eligible for treatment with ELAHERE (mirvetuximab soravtansine-gynx). This test is available through the ImmunoGen sponsored FOLR1 testing program initiative called FR-ASSIST. A separate test request form is required. Please visit the FOLR1 Ovarian Cancer Testing Program page for more information and to download the Test Request Form.

Turnaround time
Global: 2 Days, Tech-Only (stain only): 1 Day

Level of Service

  • Global
New York Approved: Yes

Storage and Transportation

Use cold pack for transport, making sure cold pack is not in direct contact with specimen. NYS clients please provide date and time of Collection.

CPT Code(s)*

Inquire for Testing Program details.

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.

Last Updated: June 24, 2025

Get in touch

Our Client Services team is on hand to help. Please call us at 866.776.5907, Option 3.